Tumor heterogeneity: An oncogenic driver of PDAC progression and therapy resistance under stress conditions.

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging disease usually diagnosed at advanced or metastasized stage. By this year end, there are an expected increase in 62,210 new cases and 49,830 deaths in the United States, with 90% corresponding to PDAC subtype alone. Despite advances in cancer therapy, one of the major challenges combating PDAC remains tumor heterogeneity between PDAC patients and...

Topics

Join the communities discussing this publication.

• Carcinoma, Pancreatic Ductal
• Disease Progression
• Pancreatic Neoplasms
• Phenotype
• Tumor Microenvironment